A small exploratory study tested whether 30 whole-body cryotherapy sessions shifted metabolic and hormonal markers in women across three age groups. The clearest signal was not in METRNL, but in insulin-resistance markers among women aged 60 to 70.
Why This Study Looked Beyond Cold Exposure
Metabolic risk tends to rise with age, and the body’s signals often become less precise over time. This study looked at that shift through adipocytokines, messenger proteins connected to fat tissue, hormones, and insulin sensitivity. In plain terms, these markers help show how well the body manages fuel, balance, and metabolic resilience.
The primary focus was METRNL, a circulating hormone linked in research to metabolic regulation. The authors did not frame whole-body cryotherapy as a single dramatic exposure. They studied it as a repeated protocol, delivered over time, because adaptation is rarely built in one session.
That distinction matters. A deliberate recovery ritual can create measurable stress, but the question is whether the body responds with useful change. Here, the study asked whether repeated cold exposure could shift markers tied to insulin resistance and longer-term metabolic health.
The Protocol And The Women Studied
The study included 48 women divided into three age groups: 20 to 30, 40 to 50, and 60 to 70. The youngest group included 16 women, the middle group included 18, and the oldest group included 14. This structure allowed the researchers to look for age-specific signals rather than treating all women as one uniform population.
Each participant completed 30 whole-body cryotherapy sessions. Every session lasted 3 minutes at minus 120 °C, a precise and demanding exposure. Blood samples were collected before the first session, after the 10th, 20th, and 30th sessions, and again two weeks after the final session.
The marker panel was broad. It included irisin, asprosin, leptin, adiponectin, insulin, fasting blood glucose, lipids, HOMA-IR, TyG, AIP, and the leptin-to-adiponectin ratio. Together, these measures offered a layered view of metabolic balance, from blood sugar control to lipid-related risk.
The design was prospective and uncontrolled, so the results show signals, not proof of cause. There was no non-WBC control group for comparison. That limitation keeps the interpretation grounded, which is where strong science begins.
What Changed, And What Did Not
The clearest finding was restraint. Repeated whole-body cryotherapy did not significantly change circulating METRNL in any age group. It also did not significantly shift the other measured adipocytokines overall, including markers connected to appetite, fat tissue signaling, and insulin sensitivity.
For readers looking for a simple cold exposure claim, this matters. The hormone panel stayed largely still. A premium protocol earns trust when it can hold that kind of silence without forcing a bigger conclusion than the data supports.
The meaningful signal appeared elsewhere. In women aged 60 to 70, insulin concentration and HOMA-IR showed a preliminary decrease after 20 sessions. HOMA-IR estimates insulin resistance, so a decrease points toward more efficient blood sugar regulation and steadier metabolic control.
That signal did not appear universally across all ages. It belonged to the oldest group in this study, and it appeared after a defined amount of exposure. The finding supports precision: the same protocol can meet different bodies in different ways.
Randomized controlled studies are needed to verify these exploratory observations.
What Readers Should Take From It
The findings speak most directly to senior women and readers focused on metabolic health. They suggest that repeated whole-body cryotherapy can be studied as part of a longevity conversation, especially in older postmenopausal women. They do not establish cryotherapy as a proven treatment for insulin resistance.
Small subgroup sizes, no non-WBC control group, and multiple exploratory outcomes all limit the strength of the conclusions. These are not minor details. They define the boundary between an interesting signal and a claim ready for clinical confidence.
Future randomized controlled studies are needed to test whether the insulin-related changes hold under stricter conditions. Until then, the balanced takeaway is clear: repeated cryotherapy showed a preliminary favorable metabolic signal in women aged 60 to 70, while METRNL and the broader adipocytokine panel did not meaningfully move.
Recovery deserves this kind of precision. You can value cold as a disciplined ritual and still ask for better evidence. That is how resilience matures into mastery.